Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,850.00    155.00 (2.32%)
Bid:
6,845.00
Ask:
6,850.00
Spread: 5.00 (0.073%)
Market Cap: £5.06b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

7 Nov 2012 07:00

RNS Number : 4867Q
Spirax-Sarco Engineering PLC
07 November 2012
 



News Release

 

Wednesday 7th November 2012

INTERIM MANAGEMENT STATEMENT

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st July 2012 to 6th November 2012.

 

Trading

In the four months ended 31st October, organic sales increased 6%, ahead of the rate of growth reported in the first half year. Notably, Asia Pacific and Watson-Marlow achieved strong double-digit sales growth in the period, followed by a more modest advance in the Americas and slightly reduced sales in our Europe, Middle East and Africa (EMEA) segment. Sales in sterling were ahead 2% in the first ten months of 2012, after including the impact of unfavourable currency movements and two small disposals last year.

 

As anticipated, our trading performance in the four months ended 31st October improved with operating profit 8% ahead at constant currency. Better results were particularly evident in Watson-Marlow, where the planned increases in R&D and market development costs in the first half year are unwinding in the second half. Results also improved in EMEA, as the cost base in Europe is being progressively lowered and the profitability of our Supply operations increased. For the ten months ended 31st October 2012, operating profit was therefore 2% ahead of last year at constant currency, compared with a decline of 3% for the first half year.

 

Financial position

We continue to operate with a strong balance sheet and are steadily reducing and rebalancing our stock position in Europe, although this continues to have a negative impact on the factory loading in our main manufacturing plants in the UK and France. Net cash balances at the end of October 2012 increased to £43m compared with £9m at 30th June 2012, although the interim dividend of £12m will be paid on 9th November. There were no significant events or transactions during the period that resulted in a material impact on the financial position of the Group. The principal risks and uncertainties remain those set out on pages 26 and 27 of the 2011 Annual Report.

 

Outlook

Global macro-economic conditions have weakened in recent months as reflected in slowing rates of GDP growth and industrial output in most geographic regions. Trading conditions in many of our markets have, however, remained more resilient and we have not seen softening in underlying demand. The Group has a favourable weighting to defensive industries such as food & beverage, pharmaceuticals and health care, and maintenance spending by our customers has continued to be positive, even against the deterioration in economic conditions.

 

Our business has other resilient characteristics due to our diverse geographic, industry, customer and product spread, and the large proportion of our sales that derive from maintenance or operating spend by our customers. We are seeing the improvements in our Supply organisation from the site consolidation in the UK and from the previously announced cost reduction programme in Europe, which should be complete by the year-end.

 

Although our forward visibility remains short and we are not immune to a worsening in our markets, which can be reflected fairly quickly in our mid-cycle business, the Board continues to expect the Group to make progress for the full year.

 

 

Enquiries:

Mark E Vernon, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

 

Note

All references above are to adjusted trading results that exclude non-operational items, including the previous announced restructuring costs, amortisation of acquisition-related intangible assets and acquisition and disposal costs.

 

 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBUGGBGDL
Date   Source Headline
8th Jun 20261:24 pmRNSDirector/PDMR Shareholding
1st Jun 202610:28 amRNSChange in Major Shareholding
29th May 20262:24 pmRNSUpdate on Directorships held by Company Directors
27th May 20263:30 pmRNSDirector/PDMR Shareholding
26th May 20265:24 pmRNSDirector/PDMR Shareholding
19th May 20269:16 amRNSChange in Major Shareholding
14th May 20262:47 pmRNSExternal Directorships held by Company Directors
14th May 202610:39 amRNSDirector/PDMR Shareholding
13th May 20264:12 pmRNSResult of AGM
13th May 20267:00 amRNSTrading Update
8th May 20263:42 pmRNSChange in Major Shareholding
7th May 20269:03 amRNSDirector/PDMR Shareholding
8th Apr 20262:22 pmRNSDirector/PDMR Shareholding
8th Apr 20269:30 amRNSAnnual Report and Accounts 2025 and Notice of AGM
18th Mar 20264:53 pmRNSDirector/PDMR Shareholding
11th Mar 20261:53 pmRNSTotal Voting Rights
10th Mar 20265:01 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNS2025 Full Year Results
10th Mar 20267:00 amRNS2025 Full Year Results
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
10th Feb 20269:30 amRNSChange in Director Details
6th Feb 20263:47 pmRNSDirector/PDMR Shareholding
2nd Feb 20261:50 pmRNSChange in Director Details
30th Jan 20262:19 pmRNSHolding(s) in Company
6th Jan 20263:10 pmRNSDirector/PDMR Shareholding
18th Dec 20252:12 pmRNSCorrection: Block Listing Application
18th Dec 20252:12 pmRNSCorrection: Block Listing Application
18th Dec 202510:34 amRNSBlocklisting Application
9th Dec 20252:35 pmRNSDirector/PDMR Shareholding
18th Nov 20259:40 amRNSDirector/PDMR Shareholding
13th Nov 20257:00 amRNSTrading Update
7th Nov 20251:56 pmRNSDirector/PDMR Shareholding
5th Nov 20258:39 amRNSHolding(s) in Company
22nd Oct 20257:00 amRNSBoard Appointment
7th Oct 20255:08 pmRNSDirector/PDMR Shareholding
9th Sep 20257:00 amRNSDirector/PDMR Shareholding
1st Sep 20259:35 amRNSHolding(s) in Company
12th Aug 20257:00 amRNSBoard Committee Membership Update
12th Aug 20257:00 amRNS2025 Half Year Results
7th Aug 20257:00 amRNSDirector/PDMR Shareholding
24th Jul 20254:58 pmRNSDirector/PDMR Shareholding
9th Jul 20254:26 pmRNSDirector/PDMR Shareholding
13th Jun 20253:36 pmRNSDirector/PDMR Shareholding
14th May 20254:48 pmRNSResult of AGM
14th May 20257:00 amRNSTrading Update
8th May 202511:03 amRNSDirector/PDMR Shareholding
23rd Apr 20255:13 pmRNSChange in Director Details
22nd Apr 20253:52 pmRNSDirector/PDMR Shareholding
11th Apr 20255:04 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.